ERBB2 and neoplasm: These previous reports have raised several clinicopathological factors affecting baseline sHER2 ECD levels: liver metastasis, clinical stage, primary tumor size, intestinal histology, and HER2 IHC status, reflecting distinct characteristics of HER2 positive gastric cancer [4].